期刊文献+

依托芬那酯凝胶联合替扎尼定治疗潜在胃肠道风险的急性颈肩腰部疼痛疗效及安全性研究 被引量:3

Effectiveness and Safety of Etofenamate Gel Combined with Tizanidine on the Treatment of Acute Local Painful Muscle Spasms with Potential Gastrointestinal Risk
原文传递
导出
摘要 目的观察非甾体抗炎药依托芬那酯凝胶联合中枢性肌松药替扎尼定对治疗有潜在胃肠道风险的急性痉挛性颈肩腰痛的疗效和安全性。方法 2012年3月-5月共诊断急性痉挛性颈肩痛及腰痛患者375例,依据排除标准排除33例,根据分组标准将有潜在胃肠道疾病风险者设为试验组(A组,n=63),明确无胃肠道疾病史者按照年龄、性别和疼痛部位与试验组进行配伍设为阳性对照组(B组,n=63)和安慰剂对照组(C组,n=63),未分组144例不纳入统计。试验组服用替扎尼定2 mg,2次/d,同时外用依托芬那酯凝胶5~10 cm均匀涂抹患处,3次/d;对照组服用替扎尼定2 mg,2次/d,同时口服塞来昔布0.2 g,2次/d;安慰剂对照组服用替扎尼定2 mg,2次/d,同时安慰剂1粒,2次/d。观察药物疗效和不良反应。结果 A组随访57例,平均起效时间为(2.17±0.99)d,总有效44例(77.2%),胃肠道不良反应2例(3.5%);B组随访54例,平均起效时间为(1.78±0.96)d,总有效45例(83.3%),胃肠道不良反应发生3例(5.5%);C组随访55例,平均起效时间(4.10±1.63)d,总有效35例(63.6%),胃肠道不良反应发生2例(3.6%)。结论依托芬那酯凝胶和口服非甾体抗炎药疗效和起效时间相当,胃肠道耐受性较好,联合用药效果优于单独使用肌松药。对于有潜在胃肠道风险的痉挛性颈肩腰背痛患者可选择外用非甾体抗炎药联合中枢性肌松药的治疗方案,以获得更好的疗效以及较高耐受性。 Objective To assess the effectiveness and safety of 10% etofenamate gel combined with tizanidine on the treatment of acute local painful muscle spasms(neck,shoulder,waist).Methods Between March and May,2012,375 outpatients with acute painful muscle spasms were included,in whom 63 were selected with potential gastrointestinal risk as group A and treated with etofenamate gel for external use(thrice per day) combined with tizanidine 2 mg(twice per day).Others were divided into group B(63 patients) and C(63 patients) randomly which had the same constituent ratio with group A on patients' age,gender,and pain location.Group B and C were treated with celecoxib 0.2 g(twice per day) combined with tizanidine 2 mg(twice per day) or placebo(1 pill,twice per day) with tizanidine 2 mg(twice per day) for 8 days respectively.The efficacy and side effects were observed.Results There were 57,54 and 55 patients finished the follow-up in group A,B and C,respectively.The overall effective rates on the day 2 after administration in 3 groups were 50.8%,68.5% and 20.0%(P0.001);and on the day 8 were 77.2%,83.3% and 63.6%(P0.05),respectively.On the other side,the gastrointestinal side-effects rate in 3 groups were 3.5%,5.5% and 3.6% without significant difference(P0.05).Conclusion The etofenamate gel has the same effect compared with celecoxib,and when combines with tizanidine,it is more effective and has better toleration than tizanidine itself dose in acute painful muscle spasms patients with potential gastrointestinal risk.
出处 《华西医学》 CAS 2012年第12期1784-1787,共4页 West China Medical Journal
关键词 依托芬那酯凝胶 胃肠道风险 急性肌痉挛痛 疗效 安全性 Etofenamate Gastrointestinal risk Acute painful muscle spasms Therapeutic effect Safety
  • 相关文献

参考文献3

二级参考文献27

  • 1杨岫岩,董怡.非甾体类抗炎药与环氧化酶异构体[J].中华内科杂志,1996,35(12):834-835. 被引量:8
  • 2Carmona L,Ballina J,Gabriel R,Laffon A.The burden of musculoskeletal diseases in the general population of Spain:results from a national survey.Ann Rheum Dis 2001; 60:1040-1045.
  • 3Wilcox CM,Allison J,Benzuly K,Borum M,Cryer B,Grosser T,Hunt R,Ladabaum U,Lanas A,Paulus H,Regueiro C,Sandler RS,Simon L.Consensus development conference on the use of nonsteroidal anti-inflammatory agents,including cyclooxygenase-2 enzyme inhibitors and aspirin.Clin Gastroenterol Hepatol 2006; 4:1082-1089.
  • 4European Medicines Agency.European Medicines Agency review concludes positive benefit-risk balance for nonselective NSAIDs.London,24 October 2006.Available from:URL:http://www.emea.europa.eu/pdfs/human/press/pr/41313606.pdf.
  • 5October 2006.Available from:URL:http://www.emea.europa.eu/pdfs/human/press/pr/41313606.pdf 4 COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs NSAIDs.Available from:URL:http://www.fda.gov/cder/drug/infopage/COX2/NSAIDRxTemplate.pdf.
  • 6Arora G,Singh G,Triadafilopoulos G.Proton pump inhibitors for gastroduodenal damage related to nonsteroidal anti-inflammatory drugs or aspirin:twelve important questions for clinical practice.Clin Gastroenterol Hepatol 2009; 7:725-735.
  • 7Sturkenboom MC,Burke TA,Dieleman JP,Tangelder MJ,Lee F,Goldstein JL.Underutilization of preventive strategies in patients receiving NSAIDs.Rheumatology (Oxford) 2003; 42Suppl 3:iii23-iii31.
  • 8Smalley W,Stein CM,Arbogast PG,Eisen G,Ray WA,Griffin M.Underutilization of gastroprotective measures in patients receiving nonsteroidal antiinflammatory drugs.Arthritis Rheum 2002; 46:2195-2200.
  • 9Moore RA,Derry S,Phillips CJ,McQuay HJ.Nonsteroidal anti-inflammatory drugs (NSAIDs),cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm:review of clinical trials and clinical practice.BMC Musculoskelet Disord 2006; 7:79.
  • 10Goldstein JL,Howard KB,Walton SM,McLaughlin TP,Kruzikas DT.Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications.Clin Gastroenterol Hepatol 2006; 4:1337-1345.

共引文献16

同被引文献38

  • 1张建荣.疼痛的治疗现状[J].中国医药导报,2006,3(35):5-7. 被引量:5
  • 2凌珊,龚千锋.草乌的研究进展[J].江西中医学院学报,2011,23(3):90-94. 被引量:50
  • 3买买吐松,阿提阚.身痛逐瘀汤内服外敷治疗颈肩腰腿痛104例[J].实用中医内科杂志,2005,19(5):453-453. 被引量:2
  • 4Stanos 8P,Galluzzi KE.Topical therapies in the management pain[J].Postgrad Meal,2015,125(4 Suppl 1):25-55.
  • 5Peniston JH,Gold MS,Alwine LK.An open-Iabel,long-term tolerability trial of diclofenac sodium 1% gel in patients osteoarthritis[J]. Phys Sportsmed, 2011,39(3):31-38.
  • 6BelIamy N,Buchanan WW,Goldsmith CH,eL aL.VaLidation study of WOMAC:a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy fn patients wfth osteoarthritis of the hip or knee[J].J F{heumat or, 1988,15(12): 1833-1840.
  • 7Asghar W,Jamali F.The effect of COX-2-selective meloxicam on the myocardial,vascular and renal risks:a systematic revfew[J].lnflammopharma cology,2015,23(1): 1-16.
  • 8Stanos SP,Galluzzi KE.Topical therapies in the management of chronic pain[J].Postgrad Med,20i3,125(4 Suppl 1):25-33.
  • 9Klinge SA,Sawyer GA.Effectiveness and safety of topical versusoral nonsteroidal anti-inflammatorydrugs:a comprehensive review[J].Phys Sportsmed,2015,41(2):64-74.
  • 10Marto J,Baltazar D,Duarte A,et aI.Topical gels of etofenamate:in vitro and in vivo evaluation[J]. Pharm Dev Technol, 2014,5 : 1-6.

引证文献3

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部